Table 2

Results of Cox regression analysis of treatment retention

	Univariable analysis			Adjusted analysis
	HR	95% CI	P value	HR	95% CI	P value
JAKi to JAKi (ref: JAKi to bDMARD)	0.93	0.79 to 1.10	0.39	0.82	0.68 to 0.99	0.04
Sex (ref: female)	0.86	0.74 to 1.01	0.07	0.87	0.73 to 1.03	0.11
Age	1.00	1.00 to 1.01	0.20	1.00	1.00 to 1.01	0.27
Disease duration in years	0.99	0.99 to 1.00	0.20	0.99	0.98 to 1.00	0.16
Seropositive, RF or ACPA	1.00	0.85 to 1.17	0.96	0.95	0.81 to 1.11	0.52
≥1 previous bDMARDs (ref: 0)	1.01	0.85 to 1.20	0.88	1.05	0.88 to 1.26	0.55
Treatment duration of first JAKi, years	1.12	1.02 to 1.22	0.02	1.16	1.05 to 1.28	0.003
Concomitant csDMARD	0.73	0.64 to 0.84	<0.001	0.73	0.63 to 0.84	<0.001
GC at baseline	0.98	0.83 to 1.15	0.80	0.98	0.83 to 1.15	0.79
CDAI	1.01	1.00 to 1.01	0.06	1.01	1.00 to 1.02	0.14
HAQ-DI	1.08	0.95 to 1.23	0.22	1.02	0.85 to 1.22	0.85
Tobacco (ref: never)	1.03	0.86 to 1.24	0.73	0.99	0.82 to 1.20	0.95
Any comorbidities	1.05	0.91 to 1.22	0.50	1.01	0.85 to 1.19	0.94

Analyses were adjusted for sex, age, disease duration, seropositivity, number of previously used bDMARDs/tsDMARDs, treatment duration of first JAKi, concomitant csDMARD treatment, concomitant GC, HAQ-DI, baseline disease activity values, smoking and comorbidity.
ACPA, anticitrullinated peptide antibodies; bDMARD, biologic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GC, glucocorticoid; HAQ-DI, Health Assessment Questionnaire Disability Index; JAKi, Janus kinase inhibitor; ref, reference; RF, rheumatoid factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.